A PHASE I/II MULTICENTER, OPEN-LABEL STUDY OF CLR457, ADMINISTERED ORALLY IN ADULT PATIENTS WITH ADVANCED SOLID MALIGNANCIES
- Registry ID
- CCLR457X2101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE1
- Study type
- INTERVENTIONAL
- Sponsor
- NOVARTIS PHARMACEUTICALS CANADA INC
- Start date
- 2015-03-03
- Last update
- 2014-07-02
Conditions
- MALIGNANT SOLID TUMOURS
- SOLID TUMORS
- ADVANCED CANCERS
Related clinical trials
- KONTRAST-R: AN OPEN-LABEL, MULTI-CENTER, ROLLOVER STUDY FOR PARTICIPANTS WHO HAVE BEEN PREVIOUSLY ENROLLED INTO A NOVARTIS-SPONSORED OPNURASIB (JDQ443) STUDY AND ARE CONTINUING TO BENEFIT FROM OPNURASIB AS A SINGLE AGENT OR IN COMBINATION WITH OTHER STUDY TREATMENTS
- A PHASE 1/1B STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF AMG 436 AS MONOTHERAPY AND IN COMBINATION WITH OTHER THERAPIES IN PARTICIPANTS WITH MICROSATELLITE INSTABILITY-HIGH (MSI-H)/MISMATCH REPAIR DEFICIENT (DMMR) SOLID TUMORS
- A PHASE 1, OPEN-LABEL, MULTICENTER STUDY TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF MK-4716 AS MONOTHERAPY AND AS PART OF COMBINATION THERAPY IN PARTICIPANTS WITH KRAS-ALTERED ADVANCED OR METASTATIC SOLID TUMORS
- A PHASE 1/2 OPEN-LABEL, MULTICENTER STUDY OF ORAL GSK5460025 ALONE OR IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN ADULT PARTICIPANTS WITH MISMATCH REPAIR-DEFICIENT (DMMR) OR MICROSATELLITE INSTABILITY-HIGH (MSI-H) SOLID TUMORS
- A PHASE 2, OPEN-LABEL, MULTICENTER, TUMOR-AGNOSTIC STUDY OF MK-1084 AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB, IN PARTICIPANTS WITH KRAS G12C-MUTANT, ADVANCED SOLID TUMORS (KANDLELIT-014)
- A PHASE I OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, DOSIMETRY, AND PRELIMINARY ACTIVITY OF [177LU]LU-DFC413 AND SAFETY AND IMAGING PROPERTIES OF [68GA]GA-NNS309 IN PATIENTS WITH SOLID TUMORS
View on source registry